Site-Directed Conjugation of Antibodies to Apoferritin
Nanocarrier for Targeted Drug Delivery to Prostate Cancer Cells

J 2016

Site-Directed Conjugation of Antibodies to Apoferritin Nanocarrier for Targeted Drug Delivery to Prostate Cancer Cells

DOSTALOVA, Simona; Tereza CERNA; David HYNEK; Zuzana KOUDELKOVA; Tomáš VACULOVIČ et al.

Základní údaje

Originální název

Site-Directed Conjugation of Antibodies to Apoferritin Nanocarrier for Targeted Drug Delivery to Prostate Cancer Cells

Autoři

Vydání

ACS APPLIED MATERIALS & INTERFACES, WASHINGTON, AMER CHEMICAL SOC, 2016, 1944-8244

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

10406 Analytical chemistry

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 7.504

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14310/16:00093826

Organizační jednotka

Přírodovědecká fakulta

DOI

https://doi.org/10.1021/acsami.6b04286

UT WoS

000378195000018

EID Scopus

2-s2.0-84975299987

Klíčová slova anglicky

antibodies; apoferritin; doxorubicin; nanomedicine; targeted drug delivery

Štítky

AKR, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 5. 3. 2020 11:51, Mgr. Marie Novosadová Šípková, DiS.

Anotace

V originále

Herein, we describe a novel approach for targeting of ubiquitous protein apoferritin (APO)-encapsulating doxorubicin (DOX) to prostate cancer using antibodies against prostate specific membrane antigen (PSMA). The conjugation of anti-PSMA antibodies and APO was carried out using HWRGWVC heptapeptide, providing their site-directed orientation. The prostate cancer-targeted and nontargeted nanocarriers were tested using LNCaP and HUVEC cell lines. A total of 90% of LNCaP cells died after treatment with DOX (0.25 mu M) or DOX in nontargeted and prostate-cancer-targeted APO, proving that the encapsulated DOX toxicity for LNCaP cells remained the same. Free DOX showed higher toxicity for nonmalignant cells, whereas the toxicity was lower after treatment with the same dosage of APO-encapsulated DOX (APODOX) and even more in prostate-cancer-targeted APODOX. Hemolytic assay revealed exceptional hemocompatibility of the entire nanocarrier. The APO encapsulation mechanism ensures applicability using a wide variety of chemotherapeutic drugs, and the presented surface modification enables targeting to various tumors.

Návaznosti

LQ1601, projekt VaV

Název: CEITEC 2020 (Akronym: CEITEC2020)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CEITEC 2020

Citovat

DOSTALOVA, Simona; Tereza CERNA; David HYNEK; Zuzana KOUDELKOVA; Tomáš VACULOVIČ; Pavel KOPEL; Jan HRABETA; Zbyněk HEGER; Markéta VACULOVICOVA; Tomáš ECKSCHLAGER; Marie STIBOROVA a Vojtěch ADAM. Site-Directed Conjugation of Antibodies to Apoferritin Nanocarrier for Targeted Drug Delivery to Prostate Cancer Cells. ACS APPLIED MATERIALS & INTERFACES. WASHINGTON: AMER CHEMICAL SOC, 2016, roč. 8, č. 23, s. 14430-14441. ISSN 1944-8244. Dostupné z: https://doi.org/10.1021/acsami.6b04286.

@article{1374952,
   author = {Dostalova, Simona and Cerna, Tereza and Hynek, David and Koudelkova, Zuzana and Vaculovič, Tomáš and Kopel, Pavel and Hrabeta, Jan and Heger, Zbyněk and Vaculovicova, Markéta and Eckschlager, Tomáš and Stiborova, Marie and Adam, Vojtěch},
   article_location = {WASHINGTON},
   article_number = {23},
   doi = {https://doi.org/10.1021/acsami.6b04286},
   keywords = {antibodies; apoferritin; doxorubicin; nanomedicine; targeted drug delivery},
   language = {eng},
   issn = {1944-8244},
   journal = {ACS APPLIED MATERIALS & INTERFACES},
   title = {Site-Directed Conjugation of Antibodies to Apoferritin Nanocarrier for Targeted Drug Delivery to Prostate Cancer Cells},
   volume = {8},
   year = {2016}
}

TY  - JOUR
ID  - 1374952
AU  - Dostalova, Simona - Cerna, Tereza - Hynek, David - Koudelkova, Zuzana - Vaculovič, Tomáš - Kopel, Pavel - Hrabeta, Jan - Heger, Zbyněk - Vaculovicova, Markéta - Eckschlager, Tomáš - Stiborova, Marie - Adam, Vojtěch
PY  - 2016
TI  - Site-Directed Conjugation of Antibodies to Apoferritin Nanocarrier for Targeted Drug Delivery to Prostate Cancer Cells
JF  - ACS APPLIED MATERIALS & INTERFACES
VL  - 8
IS  - 23
SP  - 14430-14441
EP  - 14430-14441
PB  - AMER CHEMICAL SOC
SN  - 19448244
KW  - antibodies
KW  - apoferritin
KW  - doxorubicin
KW  - nanomedicine
KW  - targeted drug delivery
N2  - Herein, we describe a novel approach for targeting of ubiquitous protein apoferritin (APO)-encapsulating doxorubicin (DOX) to prostate cancer using antibodies against prostate specific membrane antigen (PSMA). The conjugation of anti-PSMA antibodies and APO was carried out using HWRGWVC heptapeptide, providing their site-directed orientation. The prostate cancer-targeted and nontargeted nanocarriers were tested using LNCaP and HUVEC cell lines. A total of 90% of LNCaP cells died after treatment with DOX (0.25 mu M) or DOX in nontargeted and prostate-cancer-targeted APO, proving that the encapsulated DOX toxicity for LNCaP cells remained the same. Free DOX showed higher toxicity for nonmalignant cells, whereas the toxicity was lower after treatment with the same dosage of APO-encapsulated DOX (APODOX) and even more in prostate-cancer-targeted APODOX. Hemolytic assay revealed exceptional hemocompatibility of the entire nanocarrier. The APO encapsulation mechanism ensures applicability using a wide variety of chemotherapeutic drugs, and the presented surface modification enables targeting to various tumors.
ER  -

DOSTALOVA, Simona; Tereza CERNA; David HYNEK; Zuzana KOUDELKOVA; Tomáš VACULOVIČ; Pavel KOPEL; Jan HRABETA; Zbyněk HEGER; Markéta VACULOVICOVA; Tomáš ECKSCHLAGER; Marie STIBOROVA a Vojtěch ADAM. Site-Directed Conjugation of Antibodies to Apoferritin Nanocarrier for Targeted Drug Delivery to Prostate Cancer Cells. \textit{ACS APPLIED MATERIALS \&{}amp; INTERFACES}. WASHINGTON: AMER CHEMICAL SOC, 2016, roč.~8, č.~23, s.~14430-14441. ISSN~1944-8244. Dostupné z: https://doi.org/10.1021/acsami.6b04286.

Přehled o publikaci